CARGO Therapeutics, Inc. Common Stock

$4.47 USD

$0 (0.0%)

Volume: 9.53M
Average Volume: 1.68M
Market Capitalization: $216.19M
P/E Ratio: -1.59
Dividend Yield: 0.00%
Price Target: $28.00

Year High: $25.45
Year Low: $3.00
Day High: —
Day Low: —
Payout Ratio: $0.00
Current Ratio: $12.37

Industry, Sector & symbol

Stock Exchange	NASDAQ
CEO	Anup Radhakrishnan
Industry	Biotechnology
Sector	Healthcare
Current Symbol	CRGX
CUSIP	14179K101
CIK	0001966494
Web	https://cargo-tx.com
Phone	650-379-6143
Currency	USD
Employees	167
Country	US

Liquidity

Debt-to-Equity Ratio	0.00
Payout Ratio	0.00
Current Ratio	12.37
Quick Ratio	12.37
Cash Ratio	5.15

Sales & Book Value

Annual Sales	-$
Price / Sales	0.00
Cash Flow	-2.43
Price / Cash Flow	-1.85
Price / Book	0.91

Price Target and Rating

Average Stock Price Forecast	$28.00
High Stock Price Forecast	$34.00
Low Stock Price Forecast	$7.00
Forecast Upside/Downside	-84.04%
Consensus Rating	N/A
Rating Score(0-5)	0
Research Coverage	7 Analysts

Profitability

EPS (Most Recent Fiscal Year)	-$3.72
Trailing P/E Ratio	-1.59
PEG Ratio	0.06
P/E Growth	0.06
Net Income	-$167.5M
Net Margin	0.00%
Pretax Margin	0.00%
Return on Equity	-51.69%
Return on Assets	-51.98%

Financials Score

AltmanZ Score	3.06
Piotroski Score	2.00
Working Capital	237.7M
Total Assets	258.6M
Ebit	-145.29M
Market Cap	216.19M
Total Liabilities	20.91M

Poll Results

About CARGO Therapeutics, Inc. Common Stock (NASDAQ:CRGX) Stock

CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headqu ... artered in San Mateo, California.

Frequently Asked Questions

What is the current CARGO Therapeutics, Inc. Common Stock (CRGX) stock price?: CARGO Therapeutics, Inc. Common Stock(NASDAQ:CRGX) stock price is $4.47 in the last trading session. During the trading session, CRGX stock reached the peak price of $25.45 while $3 was the lowest point it dropped to. The percentage change in CRGX stock occurred in the recent session was 0.0% while the dollar amount for the price change in CRGX stock was $0.
CRGX's industry and sector of operation?: The NASDAQ listed CRGX is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of CRGX?: Anup Radhakrishnan | Interim Chief Executive Officer, Chief Financial Officer, Secretary & Chief Operating Officer
Crystal L. Mackall | Co-Founder & Scientific Advisory Board Chair
Louai Labanieh | Founder
Michael Ports | Chief Scientific Officer
Robbie Majzner | Co-Founder & Scientific Advisory Board Member
How many employees does CRGX have?: Number of CRGX employees currently stands at 167. CRGX operates from 1900 Alameda De Las Pulgas, San Mateo, DE 94403, US.

Link for CRGX official website?: Official Website of CRGX is: https://cargo-tx.com
How do I contact CRGX?: CRGX could be contacted at phone #650-379-6143 and can also be accessed through its website. CRGX operates from 1900 Alameda De Las Pulgas, San Mateo, DE 94403, US.
How many shares of CRGX are traded daily?: The average number of CRGX shares traded daily for last 3 months was 1.68M.
What is the market cap of CRGX currently?: The market value of CRGX currently stands at $216.19M with its latest stock price at $4.47